India has approved Pluvicto, the first radioligand therapy for advanced prostate cancer, marking a major step in precision oncology treatment. BulletsIn India has introduced structured access framework for Pluvicto radioligand therapy, enabling regulated distribution across selected nuclear medicine centres and hospitals nationwide. Pluvicto uses Lutetium-177 targeting PSMA-positive prostate cancer cells, delivering radiation precisely while minimizing